Daytona Street Capital LLC Invests $749,000 in Alpha Tau Medical Ltd. $DRTS

Daytona Street Capital LLC purchased a new position in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 151,227 shares of the company’s stock, valued at approximately $749,000. Daytona Street Capital LLC owned approximately 0.18% of Alpha Tau Medical at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Apella Capital LLC bought a new position in shares of Alpha Tau Medical during the 4th quarter worth $1,892,000. Levin Capital Strategies L.P. boosted its position in Alpha Tau Medical by 6.3% during the third quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company’s stock valued at $923,000 after purchasing an additional 12,200 shares in the last quarter. Mariner LLC boosted its position in Alpha Tau Medical by 185.8% during the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after purchasing an additional 80,129 shares in the last quarter. Millennium Management LLC bought a new stake in Alpha Tau Medical during the third quarter valued at about $170,000. Finally, Bank of America Corp DE boosted its position in Alpha Tau Medical by 2,779.1% during the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after purchasing an additional 21,677 shares in the last quarter. Institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Price Performance

Shares of NASDAQ DRTS opened at $6.83 on Tuesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.45 and a current ratio of 7.45. The company has a market cap of $579.32 million, a PE ratio of -12.89 and a beta of 1.04. The business has a 50-day simple moving average of $7.20 and a two-hundred day simple moving average of $5.56. Alpha Tau Medical Ltd. has a fifty-two week low of $2.43 and a fifty-two week high of $8.60.

Alpha Tau Medical (NASDAQ:DRTS) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). As a group, equities analysts expect that Alpha Tau Medical Ltd. will post -0.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on DRTS shares. Zacks Research raised Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 17th. Citigroup raised their price objective on Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Alpha Tau Medical in a research report on Tuesday, March 10th. Piper Sandler reaffirmed a “neutral” rating and set a $5.00 price objective on shares of Alpha Tau Medical in a research report on Wednesday, March 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $8.67.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.